ZURICH, Oct 28 (Reuters) – Swiss generic drugmaker Sandoz on Wednesday lowered its full-year sales growth guidance and lifted its core earnings margin forecasts after short-term biosimilar-supply
(The article has been published through a syndicated feed. Except for the headline, the content has been published verbatim. Liability lies with original publisher.)
VIDEO SHOWS: HIGHLIGHTS FROM GAME FOUR OF THE MLB WORLD SERIES BETWEEN THE TAMPA BAY…
HEINEKEN CFO HAROLD VAN DEN BROEK: WE MAY NOT SEE HUGE GROWTH RATES IN VIETNAM…
By Yadarisa Shabong and Richa Naidu LONDON, Oct 28 (Reuters) - Unilever raised its annual…
HEFEI, China, Oct 28 (Reuters) - Volkswagen is bringing China-developed technologies to overseas markets including…
Oct 28 (Reuters) - Per Aarsleff Holding A/S: * WINS COMPLEX CLIMATE PROTECTION PROJECT IN…
VIDEO SHOWS: BOTTLED DRINKS WITH PRINTED IMAGES OF FRENCH SOCCER PLAYER KYLIAN MBAPPE / PHOTOS…